Daylife Select
A point & click tool to create dynamic content portals. Learn More »
Editor's Picks
There is no pinned content in this Editor's Picks module.
Click here to learn more about content pinning.
About Novartis
Wikipedia
There are no results for this module. Edit this module to change the search term used to query Wikipedia
Related Photos
prev
next
-
AP Photo
Daniel Vasella, CEO Novartis, left, smiles next to Raymund Breu, Chief Financial Officer, right, during the 2008 full-year results press conference in Basel, Switzerland, Wednesday, Jan. 28, 2009.
View Photo » -
Getty Images
Swiss drug maker Novartis' vaccine and diagnostcs chief Andrin Oswald (L) and former World Health Organization (WHO) flu chief, now Novartis vaccine development specialist Klaus Stoehr wait before meeting with United Nations Secretary-General Ban Ki-moon and WHO Director-General Margare...
View Photo » -
Getty Images
Swiss drug maker Novartis' vaccine and diagnostcs chief Andrin Oswald (L) and former World Health Organization (WHO) flu chief, now Novartis vaccine development specialist Klaus Stoehr (2nd L) wait with other pharmaceutical company representatives before meeting with United Nations Secr...
View Photo » -
Getty Images
Swiss drug maker Novartis' vaccine and diagnostcs chief Andrin Oswald (L) and former World Health Organization (WHO) flu chief, now Novartis vaccine development head Klaus Stoehr wait before meeting with United Nations Secretary-General Ban Ki-moon and WHO Director- General Margaret Cha...
View Photo » -
Reuters Pictures
Swiss drugmaker Novartis Chief Financial Officer (CFO) Raymond Breu addresses the annual general shareholders meeting in Basel February 24, 2009.
View Photo » -
Reuters Pictures
Swiss drugmaker Novartis Chief Financial Officer (CFO) Raymond Breu (L) stands next to Chief Executive Officer (CEO) Daniel Vasella as he addresses the annual general shareholders meeting in Basel February 24, 2009.
View Photo » -
Reuters Pictures
Swiss drugmaker Novartis Chief Executive Officer (CEO) Daniel Vasella is pictured on a giant screen as he addresses the annual general shareholders meeting in Basel February 24, 2009.
View Photo » -
Reuters Pictures
Swiss drugmaker Novartis Chief Executive Officer (CEO) Daniel Vasella is pictured on a giant screen as he addresses the annual general shareholders meeting in Basel February 24, 2009.
View Photo » -
Reuters Pictures
Swiss drugmaker Novartis Chief Executive Officer (CEO) Daniel Vasella addresses the annual general shareholders meeting in Basel February 24, 2009.
View Photo » -
Reuters Pictures
Swiss drugmaker Novartis Chief Executive Officer (CEO) Daniel Vasella addresses the annual general shareholders meeting in Basel February 24, 2009.
View Photo » -
Reuters Pictures
Swiss drugmaker Novartis Chief Executive Officer (CEO) Daniel Vasella addresses the annual general shareholders meeting in Basel February 24, 2009.
View Photo » -
Reuters Pictures
Swiss drugmaker Novartis Chief Executive Officer (CEO) Daniel Vasella addresses the annual general shareholders meeting in Basel February 24, 2009.
View Photo » -
Reuters Pictures
CEO of Swiss drugmaker Novartis Daniel Vasella leaves after the annual news conference in Basel January 28, 2009. Novartis's fourth-quarter net profit rose 62 percent to $1.5 billion, driven by sales of blood pressure and cancer drugs, but missed forecasts as the strong dollar weighed.
View Photo » -
Reuters Pictures
CEO of Swiss drugmaker Novartis Daniel Vasella gestures as he addresses the annual news conference in Basel January 28, 2009.
View Photo » -
Reuters Pictures
CEO of Swiss drugmaker Novartis Daniel Vasella attends the annual news conference in Basel January 28, 2009. Novartis's fourth-quarter net profit rose 62 percent to $1.5 billion, driven by sales of blood pressure and cancer drugs, but missed forecasts as the strong dollar weighed.
View Photo » -
Reuters Pictures
CEO of Swiss drugmaker Novartis Daniel Vasella (R) addresses the annual news conference in Basel January 28, 2009. Novartis's fourth-quarter net profit rose 62 percent to $1.5 billion, driven by sales of blood pressure and cancer drugs, but missed forecasts as the strong dollar weighed.
View Photo » -
Reuters Pictures
CEO of Swiss drugmaker Novartis Daniel Vasella smiles as he addresses the annual news conference in Basel January 28, 2009.
View Photo » -
Reuters Pictures
CEO of Swiss drugmaker Novartis Daniel Vasella smiles as he addresses the annual news conference in Basel January 28, 2009.
View Photo » -
Reuters Pictures
CEO of Swiss drugmaker Novartis Daniel Vasella addresses the annual news conference in Basel January 28, 2009. Novartis's fourth-quarter net profit rose 62 percent to $1.5 billion, driven by sales of blood pressure and cancer drugs, but missed forecasts as the strong dollar weighed.
View Photo » -
Reuters Pictures
CEO of Swiss drugmaker Novartis Daniel Vasella addresses the annual news conference in Basel January 28, 2009. Novartis's fourth-quarter net profit rose 62 percent to $1.5 billion, driven by sales of blood pressure and cancer drugs, but missed forecasts as the strong dollar weighed.
View Photo » -
Reuters Pictures
CEO of Swiss drugmaker Novartis Daniel Vasella arrives for the annual news conference in Basel January 28, 2009. Novartis's fourth-quarter net profit rose 62 percent to $1.5 billion, driven by sales of blood pressure and cancer drugs, but missed forecasts as the strong dollar weighed.
View Photo » -
Getty Images
Swiss pharmaceuticals giant Novartis headquarter building is pictured on January 28, 2009 in Basel.
View Photo » -
AP Photo
Daniel Vasella, CEO of Novartis, speaks to the media during the 2008 full-year results press conference in Basel, Switzerland, Wednesday, Jan. 28, 2009.
View Photo » -
AP Photo
Daniel Vasella, CEO of Novartis, speaks to the media during the 2008 full-year results press conference in Basel, Switzerland, Wednesday, Jan. 28, 2009.
View Photo » -
AP Photo
Daniel Vasella, CEO of Novartis, speaks during the 2008 full-year results press conference in Basel, Switzerland, Wednesday, Jan. 28, 2009.
View Photo »
Getty Images
Swiss drug maker Novartis' vaccine and diagnostcs chief Andrin Oswald (L) and former World Health Organization (WHO) flu chief, now Novartis vaccine development specialist Klaus Stoehr wait before meeting with United Nations Secretary-General Ban Ki-moon and WHO Director-General Margare...
View Photo »Related Topics
Related Videos
Related Quotes
- Previous
- Next
- 1/25
-
Operating and net income are expected to reach record levels in constant currencies for the full year, even excluding the contribution from H1N1 pandemic flu vaccine sales ... However, currency-related losses could significantly reduce growth in reported results.
-
Given the totality of circumstances, the successful development, clinical testing, and large scale production of an H1N1 vaccine in such a short amount of time, despite all the challenges and uncertainties that were overcome, was a significant accomplishment for the U.S. government and Novartis Vaccines...
SOURCE: International Business Times -
Four international vaccine manufacturers — Novartis, GlaxoSmithKline (GSK), Sanofi-Aventis and Baxter International — have quoted rates to the government
SOURCE: Hindustan Times -
A fact that stands out for me – and one that's left a bitter taste – is that the government is working so closely with Daniel Vasella [CEO of Novartis]
SOURCE: Swissinfo -
HSBC and Novartis bought a lot of Tamiflu to give to their employees in case of emergency because it would be difficult to secure the medicine if swine flu starts to spread rapidly
SOURCE: FiercePharma -
We have already asked prosecutors to start a criminal investigation into HSBC and Novartis
SOURCE: France 24 -
Our mission is 'To build the Great Wall of Health for the people.' I personally look forward to working with Novartis to continue our mission by bringing more innovative vaccines to China and building Tianyuan into a true international vaccines company
SOURCE: All American Patriots -
Novartis has a long-standing commitment to improving healthcare in China. Our future activities with Tianyuan are an important step in our strategy to enhance the prevention of diseases in China with high-quality products ... The leadership and associates of Tianyuan share with Novartis the same ambitio...
SOURCE: All American Patriots -
We are also pleased to contribute to the Shanghai government's aim to establish the city as the premiere R&D center for China's bio-medicine industry by 2012, as Novartis is committed to investing to further the Chinese government's strategy for stimulating economic growth, stability and enhancing the l...
SOURCE: PR-Inside.com -
by when ... In fact, U.S. authorities said earlier this month they had received only about 23 million of the predicted 45 million vaccine doses from Novartis and other vaccine makers by mid-October. The delay has caused many U.S. states to postpone mass vaccinations, and worried patients have bombarded ...
SOURCE: CNSNews.com -
He said that it was twice the normal dose for a baby and that there was probably nothing to worry about because it was not live vaccine ... But he's basically reading the pamphlet on the vaccine from Novartis -- he's basically reading that to us over the phone.
SOURCE: Arizona Daily Sun -
Novartis’ legal challenge - mounted to limit competition to its own patented medicines - was a threat to people suffering from cancer, HIV and AIDS, diabetes and other diseases who are too poor to pay for them.
SOURCE: MyAntiWar.org -
Novartis is committed to helping patients improve their treatment compliance. Simplified treatment regimens and reduced pill burdens have been shown to help achieve this
SOURCE: PR-Inside.com -
Four pharmaceutical companies - Sanophy Pastures, Glaxo SmithKline, Baxter and Novartis -- which are lead suppliers abroad have been permitted to sell vaccines in India. They have been asked to submit clinical trial reports to the Drug Controller General of India. In the first phase, health workers who ...
SOURCE: Times of India -
We are confident that Novartis will be able to address the FDA's dosing concerns over QAB149, particularly in view of the product's recent European approval
SOURCE: International Business Times -
Novartis Animal Health is donating Sentinel Flavor Tabs to America’s VetDogs because of the vital services the dogs provide to veterans with disabilities ... Novartis appreciates the sacrifices these men and women made for their country and we want to do our part to help keep their dogs healthy.
SOURCE: PR-Inside.com -
Assistance dogs from America’s VetDogs and the Guide Dog Foundation for the Blind improve the quality of life for people with disabilities ... We want to ensure that the people we serve enjoy a long, healthy partnership with their guide or service dog, and Novartis is helping us keep these dogs healthy ...
SOURCE: PR-Inside.com -
We are very pleased with the amended terms of our agreement with Novartis which we expect will increase our revenue from Visudyne and will simplify our relationship ... This restructure will allow us to directly influence Visudyne sales in the U.S. by establishing a small focused sales force centered on...
SOURCE: News-Medical.net -
Governments have warned that an unexpected pandemic could create a public health emergency that would outstrip the capacity and speed of egg-based production methods. Some of our in-house epidemiologists and analysts fear that the current A/H1N1 2009 pandemic could peak before adequate supplies of vacci...
SOURCE: Freshnews.com -
We are very pleased that Fanapt(TM) will be commercialized in the US and Canada by Novartis Pharma, an experienced top tier pharmaceutical company with expertise in this area and extensive knowledge of the drug from its prior involvement in the development process
SOURCE: Street Insider -
The potential of GPCRs as targets for drug discovery is well recognized, but it has always been a challenge to gain structural information on GPCRs ... We believe that the power of Heptares' technology to resolve GPCR structures and their expertise in small molecule chemistry will lead to rapid progress...
SOURCE: Biospace -
This is an excellent early deal for Heptares, endorsing our StaR technology and further strengthening our financial position ... The deal with the Novartis Option Fund demonstrates confidence that our approach can unlock the potential of GCPR targets and forms a solid foundation for other partnerships w...
SOURCE: Biospace -
Preparations for the pandemic have already helped more than double worldwide vaccine manufacturing capacity to 900 million doses from 400 million, the scientists from Novartis AG, the U.S. National Institutes of Health, Erasmus University and the World Health Organization said in the article
SOURCE: Medical News Today -
As the daughter of a breast cancer survivor, I felt it was important to work with Novartis Oncology on this initiative and lend my voice to promote awareness of breast cancer and the importance of early detection
SOURCE: EURweb -
The delivery disparity raises the specter of discriminatory distribution -- serious questions about whether Novartis may be purposefully filling other flu vaccine contracts at higher levels
– 
– 
